Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2002-02-18
2008-12-16
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S135100, C424S141100, C424S142100, C424S143100, C530S387100, C530S387300, C530S388100, C530S388150, C530S388200
Reexamination Certificate
active
07465444
ABSTRACT:
Antibodies against AILIM (also called ICOS and 8F4) were found to significantly suppress the onset of inflammatory bowel diseases (especially Crohn's disease and colitis (ulcerative colitis and such)), and exhibit a significant therapeutic effect against inflammatory bowel diseases.
REFERENCES:
patent: 5484892 (1996-01-01), Tedder et al.
patent: 5506126 (1996-04-01), Seed et al.
patent: 5521288 (1996-05-01), Linsley et al.
patent: 5747461 (1998-05-01), Markov
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5914112 (1999-06-01), Bednar et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6531505 (2003-03-01), Xu et al.
patent: 2002/0115831 (2002-08-01), Tamatani et al.
patent: 2002/0164697 (2002-11-01), Coyle et al.
patent: 2002/0177191 (2002-11-01), Kroczek
patent: 2002/0182667 (2002-12-01), Kroczek
patent: 2006/0140944 (2006-06-01), Yoshinaga et al.
patent: 752433 (1999-04-01), None
patent: 198 21 060 (1999-04-01), None
patent: 19821060 (1999-04-01), None
patent: 0 984 023 (2000-03-01), None
patent: 1 125 585 (2001-08-01), None
patent: 5-72204 (1993-03-01), None
patent: 11-228442 (1999-08-01), None
patent: 2000-154151 (2000-06-01), None
patent: WO 95/33770 (1995-12-01), None
patent: WO 97/26912 (1997-07-01), None
patent: WO 98/11909 (1998-03-01), None
patent: WO 98/19706 (1998-05-01), None
patent: WO 98/37415 (1998-08-01), None
patent: WO 98/38216 (1998-09-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 99/15553 (1999-04-01), None
patent: WO 00/19988 (2000-04-01), None
patent: WO 00/46240 (2000-08-01), None
patent: WO 00/67788 (2000-11-01), None
patent: WO 01/08700 (2001-02-01), None
patent: WO 01/12658 (2001-02-01), None
patent: WO 01/15732 (2001-03-01), None
patent: WO 01/18022 (2001-03-01), None
patent: WO 01/21796 (2001-03-01), None
patent: WO 01/32675 (2001-05-01), None
patent: WO 02/44364 (2001-06-01), None
patent: WO 01/64704 (2001-09-01), None
patent: WO 01/87981 (2001-11-01), None
patent: WO 02/070010 (2002-09-01), None
patent: WO 02/076504 (2002-10-01), None
Huang Z., Pharmacology and Therapeutics, 2000, 86: 201-215.
Attwood T., Science 2000; 290:471-473.
Skolnick et al., Trends in Biotech. 2000; 18(1):34-39.
Metzler et al., Nature Structural Biol. 1997; 4:527-531.
Lewthwaite et al., Curr. Opin. Infect. Diseases, 2005, 18: 427-435.
Abbas, “T-cell stimulation: an abundance of B7s,” Nat Med. 5(12):1345-6 (1999).
Aicher et al., “Characterization of human inducible costimulator ligand expression and function,” J. of Immunology 164:4689-4696 (2000).
Akbari et al., “Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity,” Nature Medicine 8(9):1024-1032 (2002).
Andersen et al., “Allelic variation of the inducible costimulator (ICOS) gene: detection of polymorphisms, analysis of the promoter region, and extended haplotype estimation,” Tissue Antigens 61:276-285 (2003).
Ara et al., “Potent activity of soluble B7RP-1-FC in therapy of murine tumors in syngeneic hosts,” Int. J. Cancer 103:501-507 (2003).
Arimura et al., “A co-stimulatory molecule on activated T cells, H4/ICOS, delivers specific signals in Thcells and regulates their responses,” International Immunology 14(6):555-566 (2002).
Bajorath, “A molecular model of inducible costimulator protein and three-dimensional analysis of its relation to the CD28 family of T cell-specific costimulatory receptors,” J. Mol. Model 5:169-176 (1999).
Beier et al., “Induction, binding specificity and function of human ICOS,” Eur. J. Immunol. 30:3707-3717 (2000).
Bensimon et al., “Human lupus anti-DNA autoantibodies undergo essentially primary V kappa gene rearrangements,” EMBO J. 13(13):2951-62 (1994).
Bennett et al., “Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: Attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses” J. of Immunol. 170:711-718 (2003).
Bertram et al., “Role of ICOS versus CD28 in antiviral immunity,” Eur. J. Immunol. 32:3376-3385 (2002).
Biancone et al., “Lymphocyte costimulatory receptors in renal disease and transplantation,” J. Nephrol 15:7-16 (2002).
Bonhagen et al., “ICOS+Th cells produce distinct cytokines in different mucosal immune responses,” Eur. J. Immunol. 33:392-401 (2003).
Brodie et al., “LICOS, a primordial costimulatory ligand?” Current Biology 10(6):333-336 (2000).
Buonfiglio et al., “Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas,” Eur. J. Immunol. 29:2863-2874 (1999).
Buonfiglio et al., “The T cell activation molecule H4 and the CD28-like molecule ICOS are identical,” Eur. J. Immunol. 30:3463-3467 (2000).
Cameron “Recent advances in transgenic technology” Molecular Biotechnology 7:253-65 (1997).
Campbell et al., “Separable effector T cell populations specialized for B cell help or tissue inflammation,” Nat Immunol. 2(9):876-81 (2001).
Carreno et al., “The B7 family of ligands and its receptors,” Annu. Rev. Immunol. 20:29-53 (2000).
Chambers, “The expanding world of co-stimulation: the two-signal model revisited,” Trends in Immunology 22(4):217-223 (2001).
Chapoval et al., “B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production,” Nat Immunol. 2(3):269-74 (2001).
Cocks et al., “A novel receptor involved in T-cell activation,” Nature, 376:260-263 (1995).
Coyle et al., “The CD28-related molecule ICOS is required for effective T cell-dependent immune responses,” Immunity 13:95-105 (2000).
Deng et al., “Critical role of CD81 in cognate T-B cell interactions leading to Th2 response,” International Immunology 14(5):513-523 (2002).
Dong et al., “B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,” Nat. Med. 5(12):1365-9 (1999).
Dong et al., “Cutting Edge: Critical role of inducible costimulator in germinal center reactions” The J. Immunol. 166:3659-3662 (2001).
Dong et al., “ICOS co-stimulatory receptor is essential for T-cell activation and function,” Nature 409:97-101 (2001).
Eljaschewitsch et al., “Identification of a novel activation antigen on human CD4+ T cells,” Immunobiol., 194(1-3):27 (1995).
Feito et al., “Mechanisms of H4/ICOS costimulation: effects on proximal TCR signals and MAP kinase pathways,” Eur. J. Immunol. 33:204-214 (2003).
Flesch, “Inducible costimulator (ICOS),” J. of Biol. Regul.Homeost. Agents 16:214-216 (2002).
Flesch, “Inducible costimulator-ligand (ICOS-L),” J. of Biol. Regul.Homeost. Agents 16:217-219 (2002).
Frauwirth et al., “Activation and inhibition of lymphocytes by costimulation,” J. of Clin. Invest. 109(3):295-299 (2002).
Fujisawa et al., “Presence of high contents of thymus and activation-regulated . . . dermatitis,” J. Allergy of Clin. Immunol. 110(1):139-146 (2002).
Goding, “Monoclonal Antibodies: Principles and Practice,” 2ndEdition, Academic Press, Orlando, Florida, Chapter 8, pp. 281-293 (1986).
Goni et al., “Structural and idiotypic characterization of the L chains of human 1gM autoantibodies with different specificities,” J. Immunol. 142(9):3158-63 (1989).
Gonzalo et al., “Cutting edge: The related molecules CD28 inducible costimulator deliver both unique and complementary signals required for optimal T cell activation,” J. of Immunol. 166:1-5 (2001).
Gonzalo et al., “ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses,” Nat Immunol. 2(7):597-604 (2001).
Greenwald et al., “Cutting edge: Inducible costimulator protein regulates both Th1 and Th2 responses t
Fish & Richardson P.C.
Japan Tobacco Inc.
Ouspenski Ilia
LandOfFree
Methods of suppressing or treating an inflammatory bowel... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of suppressing or treating an inflammatory bowel..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of suppressing or treating an inflammatory bowel... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4052026